Peroxisome proliferator-activated receptors: New players in the field of reproduction

American Journal of Reproductive Immunology

Volumn 58, Issue 3, 2007, Pages 289-310

  Toth, Bettina ^a   Hornung, Daniela ^b   Scholz, Christoph ^a   Djalali, Schima ^b   Friese, Klaus ^a   Jeschke, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Disturbed pregnancy; Infertility; Peroxisome proliferator activated receptor; Placenta; Reproduction

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ANTIANDROGEN; ANTIINFLAMMATORY AGENT; CIGLITAZONE; CLOMIFENE CITRATE; DIANE; FOLLITROPIN; GESTAGEN; GLITAZONE DERIVATIVE; HORMONE RECEPTOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHENYLACETIC ACID; PIOGLITAZONE; PLACEBO; PROSTAGLANDIN J2; ROSIGLITAZONE; TROGLITAZONE;

ABDOMINAL PAIN; ANEMIA; ANKLE EDEMA; ANXIETY; ASTHENIA; BLOATING; BODY MASS; BODY WEIGHT; BREAST DISEASE; CELL DIFFERENTIATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; ENDOMETRIOSIS; FEMALE INFERTILITY; FETUS DEVELOPMENT; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GYNECOLOGIC SURGERY; HAND EDEMA; HEART FAILURE; HIRSUTISM; HUMAN; HYPERINSULINEMIA; IMMUNOREGULATION; KINESIOTHERAPY; LEG EDEMA; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NIDATION; NONHUMAN; OFF LABEL DRUG USE; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PLACENTA DEVELOPMENT; PREECLAMPSIA; PREGNANCY DISORDER; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR OCCUPANCY; REPRODUCTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; TROPHOBLAST; UNSPECIFIED SIDE EFFECT; VOMITING; WAIST HIP RATIO; WEIGHT GAIN;

ANIMALS; FEMALE; FETAL DEVELOPMENT; HUMANS; INSULIN RESISTANCE; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PREGNANCY; PREGNANCY COMPLICATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCTION;

EID: 34547886521     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2007.00514.x     Document Type: Review

References (173)

1. Lehrke M, Lazar MA: The many faces of PPAR gamma. Cell 2005; 123: 993-999.
2. Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 581-589.
3. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P: PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341-1349.
4. Meirhaeghe A, Amouyel P: Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 2004; 83: 93-102.
5. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
6. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071-8076.
7. Ricote M, Huang JT, Welch JS, Glass CK: The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/ macrophage function. J Leukoc Biol 1999; 66: 733-739.
8. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
9. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
10. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
11. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 2003; 100: 131-136.
12. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, FreemAn BA: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A 2005; 102: 2340-2345.
13. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
14. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
15. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97: 2553-2561.
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
17. Scheen AJ: Hepatotoxicity with thiIzolidinediones: is it a class effect? Drug Saf 2001; 24: 873-888.
18. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
19. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
20. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ: Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003; 111: 737-747.
21. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR: Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112: 608-618.
22. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A: Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72: 282-285.
23. Glintborg D, Stoving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, Flyvbjerg A, Andersen M: Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 5605-5612.
24. Lord JM, Flight IH, Norman RJ: Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; 3: CD003053.
25. Demirturk F, Aytan H, Caliskan AC, Aytan P, Koseoglu DR: Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006; 13: 58-62.
26. Hornung D, Chao VA, Vigne JL, Wallwiener D, Taylor RN: Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest 2003; 55: 20-24.
27. Lebovic DI, Kir M, Casey CL: Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004; 82(Suppl. 3):1008-1013.
28. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998; 95: 8806-8811.
29. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352.
30. Chang TH, Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129-1138.
31. Annicotte JS, Culine S, Fajas L: Role of PPAR gamma in the control of prostate cancer growth: A new approach for therapy. Bull Cancer 2007; 94: 135-137.
32. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
33. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S: Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003; 52: 910-917.
34. Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, Tapanainen JS, Laakso M: Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod 2003; 18: 540-543.
35. Dogan S, Machicao F, Wallwiener D, Haering HU, Diedrich K, Hornung D: Association of peroxisome proliferator-activated receptor gamma 2 Pro-12-Ala polymorphism with endometriosis. Fertil Steril 2004; 81: 1411-1413.
36. Fournier T, Handschuh K, Tsatsaris V, Evain-Brion D: Involvement of PPAR gamma in human trophoblast invasion. Placenta 2007; 28 Suppl A:576-581.
37. Fournier T, Tsatsaris V, Handschuh K, Evain-Brion D: PPARs and the placenta. Placenta 2007; 28: 65-76.
38. Schaiff WT, Barak Y, Sadovsky Y: The pleiotropic function of PPAR gamma in the placenta. Mol Cell Endocrinol 2006; 249: 10-15.
39. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-595.
40. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597-609.
41. Rodie VA, Young A, Jordan F, Sattar N, Greer IA, Freeman DJ: Human placental peroxisome proliferator-activated receptor delta and gamma expression in healthy pregnancy and in preeclampsia and intrauterine growth restriction. J Soc Gynecol Investig 2005; 12: 320-329.
42. Waite LL, Louie RE, Taylor RN: Circulating activators of peroxisome proliferator-activated receptors are reduced in preeclamptic pregnancy. J Clin Endocrinol Metab 2005; 90: 620-626.
43. Valle RF,TSciarra JJ: Endometriosis: treatment strategies. Ann N Y Acad Sci 2003; 997: 229-239.
44. Halme J, Becker S, Hammond MG, Raj MH, Raj S: Increased activation of pelvic macrophages in infertile women with mild endometriosis. Am J Obstet Gynecol 1983; 145: 333-337.
45. Klein NA, Pergola GM, Rao-Tekmal R, Dey TD, Schenken RS: Enhanced expression of resident leukocyte interferon gamma mRNA in endometriosis. Am J Reprod Immunol 1993; 30: 74-81.
46. Cirkel U, Ochs H, Mues B, Zwadlo G, Sorg C, Schneider HP: Inflammatory reaction in endometriotic tissue: An immunohistochemical study. Eur J Obstet Gynecol Reprod Biol 1993; 48: 43-50.
47. Khorram O, Taylor RN, Ryan IP, Schall TJ, Landers DV: Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis. Am J Obstet Gynecol 1993; 169: 1545-1549.
48. Hornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED, Taylor RN: Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab 1997; 82: 1621-1628.
49. Hornung D, Klingel K, Dohrn K, Kandolf R, Wallwiener D, Taylor RN: Regulated on activation, normal T-cell-expressed and -secreted mRNA expression in normal endometrium and endometriotic implants: Assessment of autocrine/paracrine regulation by in situ hybridization. Am J Pathol 2001; 158: 1949-1954.
50. Hornung D, Waite LL, Ricke EA, Bentzien F, Wallwiener D, Taylor RN: Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis. J Clin Endocrinol Metab 2001; 86: 3108-3114.
51. Pritts EA, Zhao D, Sohn SH, Chao VA, Waite LL, Taylor RN: Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil Steril 2003; 80: 415-420.
52. Wanichkul T, Han S, Huang RP, Sidell N: Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells. Fertil Steril 2003; 79(Suppl. 1):763-769.
53. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241: 270-274.
54. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, Auwerx J, Weissenbach J, Capeau J, Magre J: Human peroxisome proliferator-activated receptor-gamma2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 1998; 47: 490-492.
55. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M: The Pro12Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50: 891-894.
56. Kiyomizu M, Kitawaki J, Obayashi H, Ohta M, Koshiba H, Ishihara H, Honjo H: Association of two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene with adenomyosis, endometriosis, and leiomyomata in Japanese women. J Soc Gynecol Investig 2006; 13: 372-377.
57. Crosignani P, Olive D, Bergqvist A, Luciano A: Advances in the management of endometriosis: An update for clinicians. Hum Reprod Update 2006; 12: 179-189.
58. Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL: Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997; 68: 860-864.
59. Chilton R, Chiquette E: Thiazolidinediones and cardiovascular disease. Curr Atheroscler Rep 2005; 7: 115-120.
60. Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U: Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study. Rheumatology (Oxford) 2005; 44: 126-129.
61. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P: Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004; 151: 173-178.
62. Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29: 1016-1023.
63. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP: Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study. Breast Cancer Res Treat 2003; 79: 391-397.
64. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD: An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001; 96: 3323-3328.
65. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR: Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 2004; 27: 1324-1329.
66. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201: 1205-1215.
67. Lanham MS, Lebovic DI, Domino SE: Contemporary medical therapy for polycystic ovary syndrome. Int J Gynaecol Obstet 2006; 95: 236-241.
68. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
69. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R: Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75: 53-58.
70. Yildiz BO, Yarali H, Oguz H, Bayraktar M: Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2031-2036.
71. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18: 1210-1218.
72. Mitkov M, Pehlivanov B, Terzieva D: Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126: 93-98.
73. Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C: Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005; 52: 299-308.
74. Mehta RV, Patel KS, Coffler MS, Dahan MH, Yoo RY, Archer JS, Malcom PJ, Chang RJ: Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. J Clin Endocrinol Metab 2005; 90: 2136-2141.
75. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, Parra A: Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1360-1365.
76. Yilmaz M, Biri A, Karakoc A, Toruner F, Bingol B, Cakir N, Tiras B, Ayvaz G, Arslan M: The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest 2005; 28: 1003-1008.
77. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L: Direct thiazolidinedione action in the human ovary: Insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005; 90: 6099-6105.
78. Froment P, Touraine P: Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR Res 2006; Nov. 2006.
79. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R, Nawata H: Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 2000; 271: 710-713.
80. Veldhuis JD, Zhang G, Garmey JC: Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. J Clin Endocrinol Metab 2002; 87: 1129-1133.
81. Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Yetkin I, Ayvaz G, Cakir N, Arslan M: Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 206-210.
82. Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Cakir N, Arslan M: Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22: 336-342.
83. Orio F Jr, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, Savastano S, Zullo F, Colao A, Vettor R, Lombardi G: Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5110-5115.
84. Orio F Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V, Savastano S, Zullo F, Colao A, Lombardi G: Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5887-5892.
85. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, Knebel B, Muller-Wieland D, Mann K, Janssen OE: The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 62: 573-579.
86. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S: Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod 2005; 20: 1590-1595.
87. Thamer C, Machicao F, Fritsche A, Stumvoll M, Haring H: No influence of the PPARgamma2 Pro12Ala genotype on serum adiponectin concentrations in healthy Europeans. Metabolism 2003; 52: 798.
88. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA: Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002; 87: 772-775.
89. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC: Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006; 21: 121-128.
90. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618-1625.
91. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-3306.
92. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116.
93. Mitwally MF, Kuscu NK, Yalcinkaya TM: High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999; 14: 2700-2703.
94. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K: Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999; 71: 323-327.
95. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632.
96. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN: Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 932-937.
97. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD: Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 576-580.
98. Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN: Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88: 5137-5144.
99. Coffler MS, Patel K, Dahan MH, Yoo RY, Malcom PJ, Chang RJ: Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003; 88: 5624-5631.
100. Brettenthaler N, De Geyter C, Huber PR, Keller U: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835-3840.
101. Guido M, Romualdi D, Suriano R, Giuliani M, Costantini B, Apa R, Lanzone A: Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004; 19: 534-539.
102. Garmes HM, Tambascia MA, Zantut-Wittmann DE: Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 317-323.
103. Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R: Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther 2006; 80: 105-114.
104. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M: Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 2007; 88: 131-138.
105. Zheng Z, Li M, Lin Y, Ma Y: Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2002; 37: 271-273.
106. Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA: Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 624-629.
107. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-566.
108. Lv L, Liu Y: Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 480-482.
109. Sepilian V, Nagamani M: Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60-65.
110. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE: Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893-902.
111. Zhang CL, Gao HY, Zhao ZG, Jia P: Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2004; 39: 173-175.
112. Yilmaz M, Karakoc A, Toruner FB, Cakir N, Tiras B, Ayvaz G, Arslan M: The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 154-160.
113. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B: Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153: 115-121.
114. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, Arslan M: The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005; 20: 3333-3340.
115. Cataldo NA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC, Reaven GM: Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod 2006; 21: 109-120.
116. Rouzi AA, Ardawi MS: A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006; 85: 428-435.
117. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC: Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: A randomized placebo-controlled study. Hum Reprod 2006; 21: 1400-1407.
118. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC: Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: A randomized placebo-controlled study. Fertil Steril 2007; 87: 202-206.
119. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainen JS, Ukkola O, Morin-Papunen L: Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: A randomized placebo-controlled study. Eur J Endocrinol 2007; 156: 263-269.
120. Shobokshi A, Shaarawy M: Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003; 10: 99-104.
121. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S: Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: A randomized study. Hum Reprod 2005; 20: 894-899.
122. Ding NZ, Teng CB, Ma H, Ni H, Ma XH, Xu LB, Yang ZM: Peroxisome proliferator-activated receptor delta expression and regulation in mouse uterus during embryo implantation and decidualization. Mol Reprod Dev 2003; 66: 218-224.
123. Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I: Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun 2004; 315: 497-501.
124. Wang Q, Fujii H, Knipp GT: Expression of PPAR and RXR isoforms in the developing rat and human term placentas. Placenta 2002; 23: 661-671.
125. Schaiff WT, Carlson MG, Smith SD, Levy R, Nelson DM, Sadovsky Y: Peroxisome proliferator-activated receptor-gamma modulates differentiation of human trophoblast in a ligand-specific manner. J Clin Endocrinol Metab 2000; 85: 3874-3881.
126. Tarrade A, Schoonjans K, Pavan L, Auwerx J, Rochette-Egly C, Evain-Brion D, Fournier T: PPARgamma/RXRalpha heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001; 86: 5017-5024.
127. Tarrade A, Lai Kuen R, Malassine A, Tricottet V, Blain P, Vidaud M, Evain-Brion D: Characterization of human villous and extravillous trophoblasts isolated from first trimester placenta. Lab Invest 2001; 81: 1199-1211.
128. Froment P, Gizard F, Defever D, Staels B, Dupont J, Monget P: Peroxisome proliferator-activated receptors in reproductive tissues: From gametogenesis to parturition. J Endocrinol 2006; 189: 199-209.
129. Marvin KW, Eykholt RL, Keelan JA, Sato TA, Mitchell MD: The 15-deoxy-delta(12,14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma (PPARgamma) is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells. Placenta 2000; 21: 436-440.
130. Berry EB, Eykholt R, Helliwell RJ, Gilmour RS, Mitchell MD, Marvin KW: Peroxisome proliferator-activated receptor isoform expression changes in human gestational tissues with labor at term. Mol Pharmacol 2003; 64: 1586-1590.
131. Julan L, Guan H, van Beek JP, Yang K: Peroxisome proliferator-activated receptor delta suppresses 11beta-hydroxysteroid dehydrogenase type 2 gene expression in human placental trophoblast cells. Endocrinology 2005; 146: 1482-1490.
132. Daoud G, Simoneau L, Masse A, Rassart E, Lafond J: Expression of cFABP and PPAR in trophoblast cells: Effect of PPAR ligands on linoleic acid uptake and differentiation. Biochim Biophys Acta 2005; 1687: 181-194.
133. Daoud G, Amyot M, Rassart E, Masse A, Simoneau L, Lafond J: ERK1/2 and p38 regulate trophoblasts differentiation in human term placenta. J Physiol 2005; 566: 409-423.
134. Schild RL, Schaiff WT, Carlson MG, Cronbach EJ, Nelson DM, Sadovsky Y: The activity of PPAR gamma in primary human trophoblasts is enhanced by oxidized lipids. J Clin Endocrinol Metab 2002; 87: 1105-1110.
135. Schild RL, Sonnenberg-Hirche CM, Schaiff WT, Bildirici I, Nelson DM, Sadovsky Y: The kinase p38 regulates peroxisome proliferator activated receptor-gamma in human trophoblasts. Placenta 2006; 27: 191-199.
136. Tontonoz P, Hu E, Spiegelman BM: Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 1995; 5: 571-576.
137. Ricote M, Welch JS, Glass CK: Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res 2000; 54: 275-280.
138. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK: Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95: 7614-7619.
139. Wendling O, Chambon P, Mark M: Retinoid X receptors are essential for early mouse development and placentogenesis. Proc Natl Acad Sci U S A 1999; 96: 547-551.
140. Pavan L, Tarrade A, Hermouet A, Delouis C, Titeux M, Vidaud M, Therond P, Evain-Brion D, Fournier T: Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARgamma in cell invasion process. Carcinogenesis 2003; 24: 1325-1336.
141. Bildirici I, Roh CR, Schaiff WT, Lewkowski BM, Nelson DM, Sadovsky Y: The lipid droplet-associated protein adipophilin is expressed in human trophoblasts and is regulated by peroxisomal proliferator-activated receptor-gamma/retinoid X receptor. J Clin Endocrinol Metab 2003; 88: 6056-6062.
142. Schaiff WT, Bildirici I, Cheong M, Chern PL, Nelson DM, Sadovsky Y: Peroxisome proliferator-activated receptor-gamma and retinoid X receptor signaling regulate fatty acid uptake by primary human placental trophoblasts. J Clin Endocrinol Metab 2005; 90: 4267-4275.
143. Lappas M, Permezel M, Rice GE: 15-Deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta 2006; 27: 1060-1072.
144. Lappas M, Yee K, Permezel M, Rice GE: Lipopolysaccharide and TNF-alpha activate the nuclear factor kappa B pathway in the human placental JEG-3 cells. Placenta 2006; 27: 568-575.
145. Goldenberg RL, Hauth JC, Andrews WW: Intrauterine infection and preterm delivery. N Engl J Med 2000; 342: 1500-1507.
146. Keelan JA, Blumenstein M, Helliwell RJ, Sato TA, Marvin KW, Mitchell MD: Cytokines, prostaglandins and parturition-a review. Placenta 2003; 24(Suppl. A):S33-S46.
147. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK: A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-763.
148. Staels B: PPARgamma and atherosclerosis. Curr Med Res Opin 2005; 21(Suppl. 1):S13-S20.
149. Dunn-Albanese LR, Ackerman WEt, Xie Y, Iams JD, Kniss DA: Reciprocal expression of peroxisome proliferator-activated receptor-gamma and cyclooxygenase-2 in human term parturition. Am J Obstet Gynecol 2004; 190: 809-816.
150. Lappas M, Permezel M, Rice GE: Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology 2005; 146: 3334-3342.
151. Hung TH, Burton GJ: HApoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia. Taiwan J Obstet Gynecol 2006; 45: 189-200.
152. Taylor RN, Varma M, Teng NN, Roberts JM: Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990; 71: 1675-1677.
153. Hubel CA: Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999; 222: 222-235.
154. Conrad KP, Miles TM, Benyo DF: Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998; 40: 102-111.
155. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L: A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127-136.
156. Brosens IA, Robertson WB, Dixon HG: The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1: 177-191.
157. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM: Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 2002; 99: 303-308.
158. Waite LL, Atwood AK, Taylor RN: Preeclampsia, an implantation disorder. Rev Endocr Metab Disord 2002; 3: 151-158.
159. Lappas M, Permezel M, Georgiou HM, Rice GE: Regulation of proinflammatory cytokines in human gestational tissues by peroxisome proliferator-activated receptor-gamma: Effect of 15-deoxy-Delta(12,14)-PGJ(2) and troglitazone. J Clin Endocrinol Metab 2002; 87: 4667-4672.
160. Waite LL, Person EC, Zhou Y, Lim KH, Scanlan TS, Taylor RN: Placental peroxisome proliferator-activated receptor-gamma is up-regulated by pregnancy serum. J Clin Endocrinol Metab 2000; 85: 3808-3814.
161. Redman CW, Sargent IL: Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 2003; 24(Suppl. A):S21-S27.
162. de Groot CJ, Murai JT, Vigne JL, Taylor RN: Eicosanoid secretion by human endothelial cells exposed to normal pregnancy and preeclampsia plasma in vitro. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 91-97.
163. Reginato MJ, Krakow SL, Bailey ST, Lazar MA: Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 1998; 273: 1855-1858.
164. Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN: Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res 2000; 6: 3241-3248.
165. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D: Activation of PPARbeta/ delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 63-69.
166. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999; 13: 1561-1574.
167. Capparuccia L, Marzioni D, Giordano A, Fazioli F, De Nictolis M, Busso N, Todros T, Castellucci M: PPARgamma expression in normal human placenta, hydatidiform mole and choriocarcinoma. Mol Hum Reprod 2002; 8: 574-579.
168. Tarrade A, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J, Rochette-Egly C, Evain-Brion D: PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 2001; 142: 4504-4514.
169. Mouihate A, Boisse L, Pittman QJ: A novel antipyretic action of 15-deoxy-Delta12,14-prostaglandin J2 in the rat brain. J Neurosci 2004; 24: 1312-1318.
170. Hase T, Yoshimura R, Mitsuhashi M, Segawa Y, Kawahito Y, Wada S, Nakatani T, Sano H: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 2002; 60: 542-547.
171. Seto-Young D, Avtanski D, Strizhevsky M, Parikh G, Patel P, Kaplun J, Holcomb K, Rosenwaks Z, Poretsky L: Interactions among peroxisome proliferator activated receptor-{gamma}, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 2007; 92: 2232-2239.
172. Sidell N, Han SW, Parthasarathy S: Regulation and modulation of abnormal immune responses in endometriosis. Ann N Y Acad Sci 2002; 955: 159-173; discussion 199-200, 396-406
173. Pritts EA, Zhao D, Ricke E, Waite L, Taylor RN: PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002; 87: 1841-1844.